This book provides a complete approach to the economics of financing medicines and policy implications for the efficiency and equity of health systems. In all health systems with majority public financing, pharmaceutical reimbursement is one of the key factors inpolicies of change and transformation of health services in order to face the future with guarantees of financial sustainability. The initial chapters seek to answer questions about the efficiency with which the public sector intervenes in the pharmaceutical industry: Isthe present system of drug patents efficient and fair? What would be the best way to control drug prices? Is it possible to encourage competition in this market for the patient's benefit? The remainder of the book provides evidence on the impact of instruments andpolicies aimed at rationalising and controlling pharmaceutical expenditure: What can we expect from the application of reference pricing systems? When, how and where should the user be made to share the cost of medicines? What economic and non-economicincentives should be applied to drug prescription? Jaume Puig-Junoy has performed an invaluable task in creating a cohesive, and analytically rigorous book of specially commissioned chapters on this pertinent topic. The Public Financing of Pharmaceuticals willappeal to academics and researchers involved in public finance, health policy, health economics, industrial organisation and the pharmaceutical markets in Europe and in the US, where there is increasing public interest in drug coverage. The book is also intended fora wide variety of professionals in the health industries and policymakers.
About the Author
Edited by Jaume Puig-Junoy, Research Centre for Economics and Health (CRES), Department of Economics and Business, Pompeu Fabra University, Spain